Erytech Pharma has announced positive results from its Phase IIb study for its lead candidate GRASPA to treat patients with pancreatic cancer.
Erytech Pharma is developing an innovative cancer treatment, which uses red blood cells to deliver drugs that target the tumor metabolism and cause starvation of tumor cells. Read more . . .